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ABSTRAK 
 
Kajian Anti Kanser Asid Koetjape yang Ditulenkan dari Sandoricum koetjape 
Merr. 
 
Barah kolorektum yang melibatkan kolon, rektum dan kanal dubur 
merupakan keadaan kemaglinan ketiga paling berbahaya di dunia. Penyakit itu 
disifatkan oleh angiogenesis yang meluas dan usikan pelbagai jenis onkogen dan 
gen-gen penghalang pertumbuhan tumor termasuk p53, Wnt, hipoksia, NFкB, Notch 
dan kinase MAP. Mensasarkan satu atau lebih laluan-laluan ini meningkatkan 
pemilihan ejen-ejen kemoterapeutik kerana laluan-laluan ini adalah penting untuk 
pertumbuhan sel-sel kanser dan percambahan. Asid koetjapik ialah seco-A-ring 
(empat gelang-A) oleanene triterpena yang wujud secara semulajadi di dalam spesis 
Sandoricum koetjape yang tumbuh di Malaysia dan di rantau Asia Tenggara. Dalam 
kajian ini, satu cara baru penulenan asid koetjapik telah dibangunkan untuk 
menghasilkan kristal-kristal tulen asid koetjapic pada kadar hasil yang tinggi. 
Struktur sebatian ini telah direlaikan dan disahkan menggunakan pelbagai kaedah 
fizikal dan kimia yang termasuk: kristalografi sinar-x, 
1
H NMR, IR dan spektra jisim, 
dan penentuan takat lebur. Kegiatan sitotoksik asid koetjapik telah ditaksir 
menggunakan ujian MTT ke atas empat jenis sel kanser manusia iaitu; karsinoma 
kolorektal (HCT 116), kanser payudara hormon sensitif (MCF 7), kanser payudara 
rintangan hormon (MDA-MB-231) dan kanser hati (Hep G2), sebagai tambahan, dua 
jenis sel normal manusia telah diuji; kolon (CCD-18Co) dan sel-sel endotelium 
pembuluh tali pusat (HUVECs). Keputusan telah menunjukkan asid koetjapik ialah 
satu agen sitotoksik sederhana tetapi mempamerkan pemilihan menentang sel HCT 
xxi 
 
116 dengan IC50 (kepekatan separuh perencat) 18.88 μg/ml. Mekanisme-mekanisme 
sel dan molekul aktiviti antikanser asid koetjapik ke atas barah kolorektum manusia 
telah dikaji. Asid koetjapik didapati telah menyebabkan ‘apoptosis’ dalam sel-sel 
barah kolorektum HCT 116. Perubahan-perubahan awal yang mengiringi proses 
apoptosis telah dikaji melalui penilaian pengaktifan caspase. Asid koetjapik didapati 
telah menyebabkan pengaktifan ‘caspase’ hilir dan ‘caspase’ huluan. Kegiatan 
apoptotik seterusnya disahkan dengan permerhatian perubahan akhir morfologi di 
dalam sel-sel yang dirawat; asid koetjapik telah menyebabkan penyerpihan nuklear 
dan pemeluwapan serta gangguan dalam fungsi mitokondria. Kesan asid koetjapik 
pada aktiviti faktor-faktor transkripsi 10 laluan utama yang terlibat dalam proses 
karsinogenesis kanser kolon dan kanser yang lain juga dikaji. Keputusan telah 
menunjukkan bahawa sebatian itu telah menyebabkan pengawalaturan menurun 
isyarat laluan-laluan Wnt, HIF-1, MAP / ERK / JNK dan MYC/Max dan 
pengawalaturan menaik isyarat laluan NFкB. Di samping itu, kajian juga telah 
dijalankan untuk menyiasat ciri-ciri ‘antiangiogenic’ asid koetjapik sebagai kanser 
kolon adalah sangat angiogenic.  
Hasil ujikaji telah menunjukkan yang asid koetjapik mempunyai kegiatan 
ʻantiangiogenicʼ yang berkesan dengan menghalang pembentukan tiub endotelium, 
penghijrahan, dan penindasan ekspresi Faktor Pertumbuhan Pembuluh Endotelial 
(VEGF). Keputusan kajian ini secara jelasnya menekankan potensi antikanser asid 
koetjapik terhadap barah kolorektum. 
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ANTICANCER STUDIES OF KOETJAPIC ACID PURIFIED FROM 
SANDORICUM KOETJAPE MERR. 
 
ABSTRACT 
 
Colorectal cancer which involves the colon, rectum and the anal canal is the third 
most common malignancy worldwide. The disease is characterized by extensive 
angiogenesis and perturbation of a variety of oncogenes and tumor suppressor genes 
including, p53, Wnt, hypoxia, NF-кB, Notch, MAP kinase. Targeting one or more of 
these pathways increases the selectivity of the chemotherapeutic agents as these 
pathways are important for cancer cells growth and proliferation. Koetjapic acid is a 
naturally occurring seco-A-ring oleanene triterpene present in the Sandoricum 
koetjape species that grows in Malaysia and the Southeast Asian region. In this 
study, a new method of koetjapic acid purification was developed to produce pure 
koetjapic acid crystals at high yield. The structure of the compound was resolved and 
confirmed using various physical and chemical methods which include: X-ray 
crystallography, 
1
H NMR, IR, and mass spectra, and melting point determination. 
The cytotoxic activity of koetjapic acid was assessed using MTT test against four 
human cancer cell lines namely; colorectal carcinoma (HCT 116), hormone sensitive 
breast cancer (MCF 7), hormone resistance breast cancer (MDA-MB-231) and liver 
cancer (Hep G2) cell lines, in addition, two normal human cell line were tested; 
colon (CCD-18Co) and umbilical vascular endothelial cells (HUVECs) . The results 
showed that KA is a modest cytotoxic agent but exhibited selectivity against HCT 
116 cell line with IC50 18.88 μg/ml. The cellular and molecular mechanisms of 
xxiii 
 
anticancer activity of koetjapic acid towards human colorectal cancer were 
investigated. Here we find that koetjapic acid induces apoptosis in HCT 116 
colorectal cancer cells. The early changes accompanying the apoptosis process were 
investigated by assessment of caspase activation. Koetjapic acid was found to cause 
activation of downstream and upstream caspases. The apoptotic activity was further 
confirmed by observing the late morphological changes in the treated cells; Koetjapic 
acid caused nuclear fragmentation and condensation as well as disruption in the 
mitochondrial functioning. We also investigated the effect of KA on the activity of 
the transcription factors of the major ten pathways involved in carcinogenesis of 
colon cancer and other cancers as well. The results showed that the compound causes 
down-regulation of Wnt, HIF-1, MAP/ERK/JNK and Myc/Max signaling pathways 
and up-regulation of the NF-кB signaling pathway.   
In addition, we also investigate the antiangiogenic properties of koetjapic acid as 
colorectal cancer is highly angiogenic. The results showed that koetjapic acid has 
significant antiangiogenic activity by inhibiting endothelial tube formation, 
migration, and suppression of Vascular Endothelial Growth Factor (VEGF) 
expression. The results of this study clearly highlight the anticancer potential of KA 
towards colorectal cancer. 
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CHAPTER 1: INTRODUCTION 
 
1.1. Cancer:  
 Cancer is a group of more than 100 different diseases which characterized by 
uncontrolled cellular growth, local tissue invasion and distant metastasis (Chabner, 
2006). It has been difficult to develop an accurate definition for cancer. The reputed 
British oncologist Willis has defined cancer as ―an abnormal mass of tissue, the growth 
of which exceeds and is uncoordinated with that of the normal tissues and persists in the 
same excessive manner after cessation of the stimuli which evoked the change‖ (Cotran 
et al., 1999). 
The mechanisms by which cancer arises are incompletely understood. The cancer 
is assumed to develop from cells in which the typical managing mechanisms of the cells 
proliferation and growth have been altered. Recent proofs strengthen the notion of 
carcinogenesis as a genetically regulated multistage process (Mediana and Fausel, 
2008). The first step in this process is ‗initiation‘ which starts by exposure of cells to 
carcinogenic substances which lead to genetic damage that, if not repaired, results in 
irreversible mutations. The mutated cells grow till formation a colony. The second stage 
is ‗promotion‘, in which carcinogens or other factors modify the environment in a way 
supports growth of mutated cells over normal cells (Mediana and Fausel, 2008). The 
next stage is ‗transformation‘ of mutated cells to cancerous cells, about 5-20 years may 
require for the transition of benign carcinogenic phase to the fully developed malignant 
stage where the cancer can be detected clinically. The last stage called ‗progression‘, 
where further genetically changes take place leading to increase the proliferation and 
metastasis (Weinberg, 1996, Compagni and Christofori, 2000). 
2 
 
1.2. Cancer Epidemiology:  
Cancer is the major public health problem in many parts of the world. Over ten 
million new cases of cancer, with over six million deaths were estimated in the year 
2000 (Parkin, 2001). The estimated numbers of cancer incidence and mortality in 2002 
were markedly increased with 10.9 million new cases and 6.7 million deaths (Parkin et 
al., 2005). Even developed countries suffering from cancer, in USA 2677860 new cases 
of cancer have been diagnosed in 2009. In that same year, more than 562,340 cancer 
related deaths occurred which represents 25% of all deaths making cancer as the second 
leading cause of death after heart diseases (Jemal et al., 2009). 
The most common cancer in men is prostate cancer which accounts for 25% of 
newly diagnosed cancer, followed by cancers of lung and bronchus, and colon and 
rectum. While the most common cancer in women is breast cancer which represents 
27% of all new cancers in women, followed by cancers of lung and bronchus, and colon 
and rectum (Jemal et al., 2009). 
Cancers of the lung and bronchus, prostate, and colorectal in men, and cancers of 
the lung and bronchus, breast, and colorectal in women are the most common fatal 
cancers. These four cancers form 50% of cancer deaths among men and women (Jemal 
et al., 2009). 
The 5-year survival rates have been increased as new drugs and treatment 
approaches have been introduced; in 1930s, only 20% of cancer patients survived five 
years or more after treatment. In 1940s the survival rates increased to 25%. During the 
1960s, the 5-years survival was 33%, and in the 1970s it was 38%. Between year 2000-
2005, 51% of cancer patients survived for five years or more (Rodriguez and Case, 
2005).   
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However, while the survival rate increases, the incidence and mortality rates also 
keep on growing (Parkin, 2001). According to WHO deaths from cancer are projected to 
continue rising. The estimated deaths in 2030 is around 12 million (Mutanen and Pajari, 
2011). This contradiction between increasing the 5-years survival rate and increasing the 
worldwide death rates due to cancer can be explained by increased life anticipation, 
since cancer incidence increases with the age (Ries et al., 2000, Jemal et al., 2009). 
 
1.3. Genetic and Molecular Basis of Cancer: 
Developing cancer cells select mutations having two basic functions: mutations 
which increase the activity of the proteins they code for or mutations which inactivate 
gene function. The gene whose activity increases by mutation is called oncogene, while 
gene inactivated by mutation is called tumor suppressor gene.   
 Oncogenes are involved in signaling pathways which stimulate proliferation, 
while human suppressor genes code for proteins which normally act as checkpoints to 
cell proliferation. These alterations occur by carcinogenic agents like radiation, 
chemicals or viruses (somatic mutations), or they may be inherited (germ-line mutation) 
(Croce, 2008, Bertram, 2000, Mediana and Fausel, 2008, Yarbro et al., 2005). 
Six major pathways must be activated or inactivated in the genes of normal cells to 
convert to cancerous cell (Hanahan and Weinberg, 2000), these are: development of 
independence in growth stimulatory signals (e.g., activation of a family of oncogenes 
called human epidermal growth factor receptor (Cohen and Carpenter, 1975)), 
development of a refractory state to growth inhibitory signals (e.g., mutations in 
suppressor genes p53 (Feng et al., 2008)), development of resistance to programmed cell 
death (e.g., over expression of Bcl-2 genes (Kroemer, 1997)), development of an infinite 
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proliferative capacity (e.g., over expression of telomeras enzyme (Holt and Shay, 
1999)), development of angiogenic potential i.e., the capacity to form new blood vessels 
and capillaries (e.g., over expression of VEGF (Folkman, 1995)), and tissue invasion 
and metastasis (e.g., over expression of Myc oncogenes (Kawashima et al., 1988)). 
Table 1.1 depicts some genes related with cancer incidence.   
 
1.4. Cell Death and Apoptosis:  
Cell death is a key event in biology. Cells die via two main processes; either 
necrosis or apoptosis (programmed cell death) (Kerr et al., 1972). Apoptosis is firmly 
regulated by complex molecular signaling systems. Apoptosis plays a key role in 
development, morphogenesis, tissue remodelling and disposing of aged or damaged 
cells. The initial definition of apoptosis was morphological: ―Dying cells exhibit a 
characteristic pattern of changes, including cytoplasmic shrinkage, active membrane 
blebbing, chromatin condensation, and, typically, fragmentation into membrane-
enclosed vesicles (apoptotic bodies)‖ (Wyllie et al., 1980). In this process the cells 
activate an intracellular death programme and kill themselves in a controlled way. 
Because apoptotic cells shrink during this process, they are rapidly digested, thus, there 
are no leakages of their contents (Raff, 1998). Figure 1.1 demonstrates the 
morphological changes occurring during the apoptosis process.  
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Table 1.1 Examples of some oncogenes and tumor suppressor genes (Kintzios, 2003). 
 
Type of gene Gene Cancer type 
Oncogene PDGF  Glioma 
Oncogene Erb-B Glioblastoma, breast 
Oncogene RET  Thyroid 
Oncogene CDKN2  Melanoma 
Oncogene Ki-ras  Lung, ovarian, colon, pancreatic 
Oncogene HPC1  Prostate 
Oncogene N-ras  Leukemia 
Oncogene N-myc  Neuroblastoma, glioblastoma 
Oncogene Bcl-1  Breast, head, neck 
Oncogene MDM2  Sarcomas 
Oncogene c-myc  Leukemia, breast, stomach,lung 
Oncogene BCR-ABL Leukemia 
Tumor suppressor gene  p53  Various 
Tumor suppressor gene  RB Retinoblastoma, bone, bladder, 
small cell lung, breast 
Tumor suppressor gene  BRCA1  Breast, ovarian 
Tumor suppressor gene  BRCA2  Breast 
Tumor suppressor gene  APC  Colon, stomach 
Tumor suppressor gene  MSH2, MSH6, 
MLH1 
Colon 
Tumor suppressor gene  DPC4  Pancreas 
Tumor suppressor gene  CDK4  Skin 
Tumor suppressor gene  VHL Kidney 
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Figure 1.1 Cell morphological changes occurring during apoptosis process (Kerr et al., 
1972). 
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In contrast, necrosis is a term that describes uncontrolled process in which death 
takes place after exposure to an acute injury. The cells swell and burst, spilling their 
content over the surrounding tissue and cause inflammation (Raff, 1998). Table 1.2 
depicts comparison between some of the major features of apoptosis and necrosis. Any 
change in apoptosis rate in the body, either increasing or decreasing may cause many 
diseases. Apoptosis hyper-activation associated with neurodegenerative diseases (e.g., 
Parkinson‘s and Alzheimer‘s syndromes), hematologic diseases (e.g., Aplastic anaemia 
and lymphocytopenia) and disease characterized with tissue damage (e.g., myocardial 
infarction). On the other hand, increasing cell survival via apoptosis inhibition is related 
to autoimmunity diseases (e.g., Systemic lupus erythematosus) and tumor growths 
(Chamond et al., 1999).  
The notion of a strong link between apoptosis and cancer developed after 
studying the tumor growth kinetics. These studies showed that changes in ‗cell loss 
factor‘ have influence on tumor growth or regression. Further studies revealed a high 
rate of apoptosis occurrence in tumors treated with cytotoxic agents that regressed after 
treatment (Kerr et al., 1972).   
Apoptosis can be induced through a number of pathways by proteins that control 
the cell cycle machinery including p53, Wnt, hypoxia, NF-қB, Notch and MAPKs 
pathways (Ghobrial et al., 2005). Any defect in these regulatory pathways have been 
related to many malignancies (Kaufmann and Hengartner, 2001). 
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Table 1.2 Comparison between some of the major features for apoptosis and necrosis 
(Devarajan, 2009). 
 
Feature Apoptosis  Necrosis  
Cell volume  Decreased  Increased  
Plasma membrane integrity  Preserved  Lost  
Plasma membrane structure  Characteristic blebbing  Lost  
Cell-cell adhesion  Lost early  Typically preserved  
Cell matrix adhesion  Lost early  Lost late  
Exfoliation of cells  Early, as single cells Late, as sheets of cells 
Chromatin   Condensed  Preserved  
Nuclear fragmentation  Characteristic  Absent  
Cytosolic contents  Preserved  Released  
Apoptotic bodies  Characteristic  Absent  
Phagocytosis  Characteristic  Absent  
Inflammatory response  Absent  Characteristic  
 
 
1.4.1. Apoptosis Pathways:  
Apoptotic signaling events can be divided into two major pathways based on the 
mechanism of initiation: the intrinsic pathway which mainly depends on mitochondrial 
changes, and the extrinsic pathway which is activated via death receptors. Although 
different molecules take part in the core machinery of both apoptosis signaling 
pathways, a crosstalk exists at multiple levels (Ghobrial et al., 2005). 
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Apoptotic caspases could be classified into two classes, effector (downstream) 
caspases, which are responsible for the cleavages that disassemble the cell, and initiator 
(upstream) caspases, which initiate the proteolytic cascade and activate the effector 
caspases. Effector caspases include caspase 3, 6 and 7; their function is cleaving the 
polypeptides that go through proteolysis in apoptosis process. Table 1.3 depicts 
examples of some cellular caspase substrates classified according to their function in 
apoptosis (Lamkanfi et al., 2002). 
Upstream caspases include caspase 8 and caspase 9. The upstream caspases can 
be initiated through the extrinsic pathway or the intrinsic pathway. The extrinsic 
pathway starts with ligation of the death receptors (e.g., CD95 (Fas) and the tumor 
necrosis factor-α receptor 1 [TNFR1], DR3, DR4, DR5, and DR6). The ligation results 
in receptor trimerization followed by binding of the adaptor molecule FADD to the 
cytoplasmic domain of the receptor. FADD in turn activates caspase 8 zymogen. The 
caspase 8 enzyme will then cleave procaspases 3 and 7 (Medema et al., 1997, Cohen, 
1997, Ghobrial et al., 2005, Boatright and Salvesen, 2003, Earnshaw et al., 1999). On 
the other hand, changes in the conformation or activity of Bcl-2 protein initiate the 
intrinsic apoptotic pathway. Bcl-2 is a protein located in the outer mitochondrial 
membrane. 
Upon activation of pro-apoptotic members of Bcl-2 such as Bak and Bax the 
mitochondrial membrane potential decreases, as a result the mitochondrial permeability 
increases which allows the releasing of cytochrome c.  
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Table 1.3 Examples of some cellular caspase substrates classified according to their 
function in apoptosis (Lamkanfi et al., 2002). 
  
Effect on the cell  Substrate  Caspase  
Disassembly of the cytoskeleton, loss of cell to 
cell contact, disintegration and fragmentation of 
the cell. 
 
 
 
 
 
Actin  
Plectin  
α-Adducin 
β-Catenin  
E-cadherin 
Desmoglein-3 
Vimentin  
Cytokeratin-18 
Fak 
8 
8 
3 
3,7,8 
3,7 
3,7 
3,6,7,9 
3,6,7 
3,7 
Blebbing of the membrane ROCK-I 3 
Nuclear breakdown  Lamin A 
Lamin B 
6 
3 
Chromatin condensation  Acinus  3 
DNA degradation  ICAD/DFF-45 3 
Loss of DNA repair  PARP 3,7,9 
Inhibition of DNA replication  DNA-RC  
Topoisomerase  
3 
3 
Disintegration of the Golgi complex  Golgin-160 2 
Inhibition of the transport from the endothelium 
reticulum to the Golgi  
BCAP31 3,8 
Disruption of the mitochondria and 
amplification of the apoptotic signal  
 
 
 
Bid 
BAX 
Bcl-2 
Bcl-XL 
3,8 
3 
3 
1,3 
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In turn, cytochrome c activates caspase 9 zymogen which activates caspases 3 and 7. 
Figure 1.2 demonstrates the extrinsic and intrinsic pathways of apoptosis process 
(Boatright and Salvesen, 2003, Inoue et al., 2009).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 The extrinsic and the intrinsic pathways of apoptosis, adopted from (Fulda 
and Debatin, 2006).  
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1.4.2. Signal Transduction Pathways in Cancer:  
Cancer cells have the ability to change the surrounding environment in a way 
that will assist them to grow and proliferate. They respond to any internal or external 
circumstances by increasing or decreasing the expression of proteins which can adjust 
the situations in favour of increasing the proliferative, invasive and metastatic properties 
(Hanahan and Weinberg, 2000). The reciprocal communications between the external or 
internal circumstances and protein expression level take place via activation of a cascade 
of intracellular biochemical reactions which is also called signal transduction pathways 
(Lobbezoo et al., 2003). Each pathway starts with ligation of extracellular receptors. The 
receptor activation is translated into biological response by activation of proteins 
(transcriptional factors) which then translocate into the nucleus and bind with the DNA 
in specific binding sites (promoters) and trigger the transcription of mRNAs which later 
translated to proteins (Eccleston and Dhand, 2006).  
Oncogenic gene mutations results in a constitutive activation of signal 
transduction elements, simulating a condition of permanent activation of the receptor, 
even in the absence of the relevant growth factor (Hanahan and Folkman, 1996).  
            Wnt, Notch, TGF-β, Myc/Max, Hypoxia, MAPK pathways were reported to be 
hyper-activated in cancerous cells (Clevers, 2004, Miyazawa et al., 2002, Fang and 
Richardson, 2005, Soucek et al., 2008, van Es and Clevers, 2005a). 
On the other hand, mutations in tumor suppressor genes lead to deactivation of 
some pathways which may serve as checkpoints of cells proliferation such as p53 (Feng 
et al., 2008). These pathways can be targeted with signal transduction modulators 
(STMs) in order to treat cancer. The STMs can modulate the pathway activity at many 
levels such as blocking cell surface receptors, blocking the mediators between 
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extracellular signals and the transcriptional factor, deactivate the binding between the 
transcriptional factors with the promoters or inhibiting the effects of further downstream 
genes (Lobbezoo et al., 2003). 
STMs have attracted attention of many researchers. Many STMs compounds are 
being investigated in preclinical studies or in clinical trials. Additionally, there are two 
approved STMs drugs which have been commercially marketed; trastuzumab and 
imatinib (Lobbezoo et al., 2003).  
 
1.4.2 (a) Wnt /β-catenin Signaling Pathway:  
Wnt signaling pathway plays a crucial role in development process as well as 
cancer by controlling gene expression, cell behaviour, cell polarity and cell adhesion 
(Cadigan and Nusse, 1997). Wnt signals work through three pathways: Wnt /β-catenin 
pathway (referred to as canonical Wnt pathway) and the non-canonical Wnt/Ca
+2
 and 
Wnt/JNK pathways (Moon et al., 2002).  
The mutations of many components of Wnt /β-catenin pathway were detected in 
many types of human cancers such as: colon cancer, melanoma, prostate and breast 
cancer (Morin et al., 1997, Verras and Sun, 2006, Lin et al., 2000, Chien et al., 2009). 
Moreover, it was found that 80% of sporadic colon cancer patients have mutation in a 
tumor suppressor gene called APC, which function was identified as a down-regulator of 
Wnt pathway (Calvert and Frucht, 2002). It is widely accepted now that mutations either 
in APC or Wnt /β-catenin pathway are the earliest events in colon oncogenesis (Kinzler 
and Vogelstein, 1996).  
The Wnt /β-catenin pathway controls the expression of a number of important 
oncogenes such as: c-Myc, cyclin D1 and matrix metalloproteinase genes which are vital 
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in carcinogenesis as well as angiogenesis (Dihlmann and Magnus, 2005). Down-
regulation of Wnt pathway with the aim of decreasing these genes expression could 
regress the tumor proliferation as verified in one study which targeted expression of 
cyclin D1 (Tetsu and McCormick, 1999).  
 
1.4.2 (b) Notch Signaling Pathway:  
Notch cell signaling pathway is involved in a variety of cellular functions such as 
cell fate
 
specification, differentiation, proliferation, apoptosis, adhesion,
 
migration, and 
angiogenesis (Bolos et al., 2007). The signaling cascade starts with the ligation of the 
extracellular four isoforms of Notch receptors (Kojika and Griffin, 2001). In the 1990s, 
the relation between Notch pathway and cancer was identified after a study which 
showed that 10% of T-cell lymphoblastic leukemia patients have constitutive activation 
of Notch 1 receptor (Callahan and Raafat, 2001). Further in vivo and in vitro studies 
supported the idea that activation of any of Notch isoforms is well-correlated with tumor 
growth and aggressiveness properties (Callahan and Raafat, 2001). Hyper-activation of 
Notch pathway signaling has been noticed in many types of cancer, including pancreas, 
breast, colon, renal, melanoma and lung cancers (Wang et al., 2006, Farnie and Clarke, 
2007, Sun et al., 2009, Radtke and Clevers, 2005, Strizzi et al., 2009, Collins et al., 
2004). 
Many studies reported the strong relation between Notch and Wnt pathways in 
colon cancer (van Es and Clevers, 2005b, De Strooper and Annaert, 2001, Fre et al., 
2009). In mutant APC mice (the tumour suppressor gene of Wnt pathway), it was found 
that Wnt pathway signaling as well as Notch pathway were hyper-activated, the results 
strengthen the hypothesis that Notch signaling might be in a downstream of Wnt 
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pathway. Moreover, the two pathways may work synergistically, hence both Notch and 
Wnt inhibitors may be combined in colon cancer treatment (van Es and Clevers, 2005b). 
Several approaches to block Notch pathway have been under investigations, among 
them: antisense, RNA interference and monoclonal antibodies (Nickoloff et al., 2003).  
 
1.4.2 (c) p53 Signaling Pathway:  
The p53 gene mutation is extremely common on all cancers; p53 is suppressed in 
more than 50% of all human cancer cases. p53 mutations causes activation of other 
oncogenic pathways, making tumor more aggressive and resistant to chemotherapy as 
well as radiation (Kumar et al., 2004). The relation of p53 and cancer was presented in 
1980s and p53 has been called as a ―Guardian of the Genome‘‘ referring to its ability in 
induction of apoptosis and cell cycle arrest. p53 protein encodes many type of genes 
which are involved in cell cycle, apoptosis and angiogenesis. p53 controls cell death by 
regulating the two apoptotic pathways genes, the death receptor Fas and DR-5 genes 
which are involved in extrinsic pathway as well as Bax, Bak and Bid proteins which are 
involved in the mitochondrial pathway (Frank et al., 2004). The impact of p53 in 
apoptosis process was demonstrated in a study which showed that the apoptosis process 
has been slowed down significantly in p53 knockout-mice and as a result the tumor 
became more drug resistance (Lowe et al., 1993).  
Restoring the p53 protein and correction its defects may perhaps be useful in 
treating cancer. Different approaches have been used which have showed remarkable 
success in many cancers such as cervical, head and neck, lung, ovarian and prostate 
(Clayman et al., 1995).  
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1.4.2 (d) TGF-β Signaling Pathway:  
TGF-β signaling pathway is described as a double-edged sword, the tumor 
suppressor and oncogenic properties of this pathway were reported in many studies 
(Akhurst and Derynck, 2001, Sánchez-Capelo, 2005, Akhurst, 2002). In term of tumor 
suppression properties of TGF-β, one study have shown that TGF-β defect- mice were 
more susceptible to tumor incidence than normal mice (Tang et al., 1998). Besides, 
transgenic mice in which the TGF-β is hyper-activated were found to be more resistant 
for mammary tumor formation (Pierce et al., 1995). On the other hand, it was confirmed 
that tumor cells secret TGF-β proteins in vitro more than normal cells (Roberts et al., 
1983). TGF-β plasma concentrations as well as TGF-β urinary excretion rate of cancer 
patients were higher than normal values (Nishimura et al., 1986, Tsushima et al., 1996). 
Additionally, a strong correlation between TGF-β concentrations and tumor metastasis, 
invasive and angiogenesis has been confirmed (Bierie and Moses, 2006). All these 
studies indicate that TGF-β has a negative impact on tumor prognosis (Tsushima et al., 
1996). Many studies conclude that the over expression of TGF-β pathway can work as 
tumor suppressor gene at the early stages of cancer, however, after that this pathway 
serve as an oncogenic pathway and supports angiogenesis, metastasis and invasive 
properties of tumor cells (Bierie and Moses, 2006, Massagué, 2008). Nevertheless, the 
obvious mechanistic explanation of the dual effects is still ambiguous. 
Targeting this pathway has shown promising results in cancer treatment, using 
techniques such as antisense and ligand-receptor binding inhibition by using antibodies 
targeting the TGF-β protein or the receptors (Massagué, 2008). However, the 
pharmaceutical companies still fear to produce any target of this pathway because of the 
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non-selectivity and potential side effects which may arise from the dual activity 
(Akhurst, 2002). 
 
1.4.2 (e) Cell Cycle (pRB/ E2F) Signaling Pathway: 
 The retinoblastoma tumor suppressor (pRB) is an essential contributor in apoptosis 
and cell cycle processes. The pRB gene which encodes pRB proteins has been found to 
be mutated in approximately 50% of all human tumors. Additionally, genes encoding 
upstream regulators of pRB have been reported to be mutated in the remaining 50% of 
all human tumors (Frank and Yamasaki, 2004). 
 Studies on retinoblastoma cases showed that more than 40 % of clinical cases are 
hereditary due to the inactivation of pRB tumor suppressor gene (Draper et al., 1992). 
Using DNA cloning techniques, the influence of pRB protein was confirmed in other 
type of cancers such as bladder, breast, lung, leukemia and prostate (Weinberg, 1991). In 
vitro experiments which involved introducing pRB protein in cancer cells causes 
inhibition of cell proliferation at stage S of the cell cycle (Bandara and La Thangue, 
1991). The role of pRB has been noticed in other types of cancer such as pituitary 
adenocarcinomas, pheochromacytomas and thyroid C-cell adenomas as have been 
shown in pRB knockout mice tumor model (Harrison et al., 1995, Nikitin et al., 1999).  
 The pRB signaling pathway is activated by binding the pRB protein with many 
transcriptional factors, among them E2F seems to be the most important (Bandara and 
La Thangue, 1991). The active dimer then binds with its promoters which control the 
expression of many vital genes involved in cell death process such as c-Myc, 
thymidylate synthase, N-Myc, cdc2, thymidine kinase, cyclin A, dihydrofolate reductase 
and DNA polymerase (Helin and Ed, 1993).  
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1.4.2 (f) NF-кB Signaling Pathway:  
NF-κB suppresses cell death and supports cell growth, metastasis and 
angiogenesis. More than 200 target NF-кB genes have been identified, among them: 
Myc, Rel, and Cyclin D1-4 which are involved in cell cycle regulation, Bcl-2, Bcl-Xl, 
A1/Bf-1 which play important roles in the apoptosis process, VEGF gene which is 
essential in angiogenesis process, and urokinase plasminogen activator which plays 
important role in cell metastasis (Pahl, 1999). Previous studies have shown that NF-кB 
safe guards tumor cells from apoptosis (Barkett and Gilmore, 1999). NF-кB knocked-out 
mice experiments proof the oncogenic roles of this pathway (Beg et al., 1995). In other 
studies, activation of this pathway inhibited tumor regression and cell apoptosis (Li et 
al., 1999, Chaisson et al., 2002, Schmidt-Supprian et al., 2000). 
The oncogonic activity of NF-кB inspired researchers to synthesize compounds 
that target this pathway; for instance, cinnamaldehyde which was reported as an 
apoptosis inducer agent acting via mitochondrial pathway, has been reported recently as 
a potent NF-кB pathway inhibitor (Hyeon et al., 2003, Reddy et al., 2004).   
 
1.4.2 (g) Myc/Max Signaling Pathway: 
Myc/Max pathway has been found to be hyper-activated in 70% of all human 
cancer cases which strongly suggesting the oncogenic nature of this pathway (Nilsson 
and Cleveland, 2003). The Myc/Max pathway was also found to play important roles in 
the cell cycle process, and the lack of this protein prevents the cell cycle from 
proceeding beyond the S phase (Heikkila et al., 1987). Besides its role in cell 
proliferation, Myc/Max also plays a role in triggering the angiogenic switch in favour of 
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angiogenesis initiation (Pelengaris et al., 1999). Dimerization with Max and then 
binding to DNA are necessary to exhibit all Myc biological effects (Evan et al., 1992). 
A significant tumor regression in transgenic mice was attained by knocking-
down the Myc/Max which paving the way to a more directed efforts in aim of targeting 
this pathway (Pelengaris and Khan, 2003).  
 
1.4.2 (h) MAPK Signaling Pathways:  
 There are three sub-families of MAPK proteins: extracellular signal regulated 
enzyme kinases (MAPK/ERK), p38 MAPKs and the c-Jun amino terminal kinase 
(JNKs). While the main function of MAPK/JNKs and MAPK/ERKs are in cell cycle, 
regulation of mitosis, migration and apoptosis, the MAPK/p38 function is involved in 
inflammation (Johnson and Lapadat, 2002).  
 The activation of these pathways is attained by ligation the extracellular receptor 
Ras. Upon activation, the MAPK signaling requires the activation of three MAPK 
chains; starting with MAPKKK which then activates MAPKK which consequently 
activates MAPK (Makin and Dive, 2001). 
 Upon treatment with MAPK signaling inhibitors, the cell cycle process is arrested 
and cell proliferation is inhibited in many cell lines such as: smooth muscle, epithelial, T 
lymphocytes, fibroblasts and hepatocytes cell lines (Meloche and Pouyssegur, 2007).  
 The mechanisms by which these pathways exhibit their functions were studied 
thoroughly. The ability of MAPKs to regulate the cell growth was explained by it is 
ability to control global protein syntheses by activating the translation of the initiation 
factor eIF4E as well as by direct regulation of ribosomal gene transcription (Stefanovsky 
et al., 2001, Morley and McKendrick, 1997). Also, it has been found that the production 
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of pyrimidine - which is important in DNA and RNA synthesis- is under the control of 
this pathway (Evans and Guy, 2004). This pathway is essential for G1- to S-phase 
progression. MAPKs also serve in stabilization of c-myc protein (Sears et al., 2000). 
Additionally, MAPKs down regulate more than 170 tumor suppressor genes such 
as: Tob1, JunD and Ddit3 which inhibit cell growth and proliferation (Yamamoto et al., 
2006).  
 Based on the crucial oncogenic activities, huge efforts were attempted in order to 
produce inhibitors of the ERK and JNK pathways, some of the them are in
 
clinical trials 
(Kohno and Pouyssegur, 2006).  
 
1.5. Angiogenesis:  
Angiogenesis research is the cutting edge technology that is currently being heavily 
exploited in the cancer field (DeWitt, 2005). Angiogenesis research will probably 
change the face of medicine in the next decades, more than 500 million people 
worldwide are expected to benefit from pro- or anti-angiogenesis treatments (Carmeliet, 
2005). Angiogenesis is a process of new blood vessel development orchestrated by a 
range of angiogenic factors and inhibitors. This process is tightly regulated and self 
limiting in some cases such as wound healing, normal growth process and reproductive 
function (Folkman and Klagsbrun, 1987). In contrast, when this process is deregulated, 
diseases such as cancer, rheumatoid arthritis, obesity and diabetic blindness can be 
formed (Carmeliet, 2005, Folkman, 1995). Angiogenesis plays an important role in 
cancer growth without which, tumors will be unable to expand beyond 1 to 2 mm
3
 
(Folkman and Cotran, 1976). Cancer cells within the tumor will then use the newly 
formed blood vessels as a port to metastasize to other localities (Weidner et al., 1991). 
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Since the interdependency and a close relationship between angiogenesis, cancer 
growth and metastasis has been well-established, much effort have been invested into 
development or discovery of antiangiogenic compounds activity to target cancer and 
variety of other angiogenic related ailments. 
 
1.5.1. The Vascular Endothelial Growth Factor (VEGF):  
As the size of the tumor increases, oxygen demand increases causing a state of 
hypoxia (Fu et al., 1976). The hypoxic state in the tumor spring forth oxygen free 
radicals which in turn activates vascular endothelial growth factor (VEGF) triggering the 
angiogenesis event (Mukhopadhyay et al., 1995). VEGF (referred to also as VEGF-A) 
had been regarded as a heparin binding angiogenic growth factor exhibiting high 
specificity for endothelial cells (Gospodarowicz et al., 1989). VEGF is responsible for 
triggering various steps in the angiogenesis cascade such as proliferation, migration and 
cell survival (Ferrara, 2002). The tumor regression and inhibition can be achieved by 
deactivating VEGF activity via neutralizing antibodies or by introduction of dominant 
negative VEGF receptors (Kim et al., 1993). The VEGF was found significantly 
upregulated at the levels of RNA and protein in most types of cancer. The high 
concentration of VEGF in cancer patients is associated with poor prognosis as well as 
with low survival (Paley et al., 1997). 
The activities of VEGF family are mediated by three tyrosine kinase receptors, 
VEGFR-1 (Flt l), VEGFR-2 (Flkl/KDR), and VEGFR-3 (Flt4) (Ferrara et al., 2003). 
VEGF –A belongs to a gene family that includes placenta growth factor (PlGF), VEGF-
B, VEGF-C, VEGF-D and VEGF-E. The main difference between these proteins is the 
type of receptors they bind and activate; PlGF, VEGF-B can bind with VEGFR-1, 
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VEGF-C and VEGF-D bind with VEGF-3, and VEGF-A can bind with two receptors: 
VEGFR-1 and VEGFR-2 (Shibuya, 2001).  
Alternative exon splicing results in five different isoforms of VEGF-A: VEGF121, 
VEGF143, VEGF165, VEGF189, and VEGF206. VEGF165 is the predominant isoform 
as well as it have the strongest signal transduction because its ability to bind with an 
extracellular molecule called neuropilin-1, the binding with neuropilin-1 results in 
increasing the affinity with VEGFR-2 to about ten folds (Park et al., 1993, Shibuya, 
2001).   
 
1.5.2. Angiogenesis Process Cascade:  
Angiogenesis is a sophisticated multistep process. Figure 1.3 illustrates the 
angiogenesis process steps. Increasing of VEGF-165 expression is crucial in initiating 
the angiogenesis process (Nagy et al., 2003). Angiogenesis starts with dilatation of blood 
vessels to increase the permeability to the angiogenesis signals. Then, the pericytes 
which covers the blood vessels, detach and the vascular basement membrane and 
extracellular matrix gets degraded (Fig.1.3b), which allow for the underlying endothelial 
cells to migrate into the perivascular space towards chemotactic angiogenic stimuli 
(Fig.1.3c) (Ko et al., 2007). The migrated endothelial cells proliferate, loosely following 
each other into the perivascular space and form migration columns (Fig.1.3d). Then, the 
endothelial cells differentiate; cells‘ shape change in a way that facilitates the cell-cell 
adherence which then forms a lumen (tube-like structure). Perivascular cells are 
attracted, and a vascular basal lamina is produced around the newly formed vessels. The 
details are still vastly obscure for the last stages when vascular sprouts fuse with other 
sprouts to form loops (Fig. 1.3e) (Bergers and Benjamin, 2003, Carmeliet, 2005). 
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1.5.3. Cancer is Angiogenesis Dependent: 
Many studies have confirmed the hypothesis that tumor growth is reliant on 
neovascularisation process. Any significant increment in tumor size must be in 
synchrony with increment in the blood supply and blood vessels size (Folkman, 1990). 
The hypothesis was confirmed by many experimental evidences. In one study, tumors 
implanted in places where there is no probability of new blood vessels to grow such as 
the aqueous fluid of the anterior chamber of the eye remained viable, avascular, and 
limited in size (<1 mm
3
). When the cells were implanted on iris vessels, they induced 
new blood vessels formation which grew hastily reaching 16,000 times their original 
size within two weeks (Gimbrone et al., 1972). Another evidence that strengthen this 
hypothesis was the detection of exponential and rapid growth of tumors that were 
implanted on the chorioallantoic membrane of the chick embryo after blood vessels 
formation (Knighton et al., 1977). Studies on subcutaneously implanted tumors showed  
 
 
 
 
 
 
 
 
 
Figure 1.3 The angiogenesis process cascade. Blood vessels grow from pre-existing 
capillaries (a). (b) First, pericytes (green) separate, blood vessels dilate and the basement 
membrane and ECM is degraded. (c) The endothelial cells (red) migrate into the 
perivascular space. (d) Endothelial cells proliferate, and are presumably guided by 
pericytes. (e) Endothelial cells adhere to each other and create a lumen (Bergers and 
Benjamin, 2003). 
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that the blood vessels form approximately 1.5% of the tumor volume; this is number 
represent 400% increase over normal subcutaneous tissue (Thompson et al., 1987). 
 
1.5.4. The Angiogenic Switch:  
About five to twenty years may be needed for transition from benign 
carcinogenic phase to the fully developed malignant stage where the cancer can be 
perceived clinically (Mediana and Fausel, 2008). Dormancy stage occurs when tumor 
cells proliferate but the rate of tumor cell death (apoptosis) counterbalances this 
proliferation and maintains the tumor mass in a steady state (Ribatti et al., 1997). At this 
stage, there are a balance between two contrary signals; angiogenesis signals like VEGF 
(Ferrara et al., 2003) and antiangiogenesis signals (e.g., Endostatin, Angiostatin) (Kim 
Lee Sim et al., 2000). Therefore, the angiogenesis process starts only when the net 
balance between these contrary signals is tipped in favour of angiogenesis initiation 
(Hanahan and Weinberg, 2000, Hanahan and Folkman, 1996). Accordingly, 
identification and interrupting of the factors and the circumstances which increase the 
probability of angiogenesis initiation may keep the cancerous cells in the stage of 
dormancy (Gullino, 1978). The studies showed that angiogenesis process can be 
triggered by a variety of signals include metabolic stress (e.g., hypoxia or 
hypoglycaemia), mechanical stress (e.g., pressure generated by proliferating cells), 
immune/inflammatory response (immune/inflammatory cells that have infiltrated the 
tissue), and genetic mutations (Hanahan and Weinberg, 2000). These circumstances 
cause synthesis or release of angiogenic factors such as VEGF (Ribatti, 2009).  
 
 
25 
 
1.5.5. Hypoxia:  
Hypoxia is defined as a decrease in the oxygen supply to a level insufficient to 
maintain cellular function. The cells become hypoxic if it is located too far away from 
blood vessels. Due to cell proliferation and tumor growth, the cells in the core of tumor 
gets hypoxic (Carmeliet, 2005). Hypoxic cells are more invasive and metastatic, and 
more resistant to be killed by chemotherapy or radiation (Melillo, 2007).  
Recent evidence demonstrated the impact of activation of hypoxia inducible 
transcription factors (HIFs) in hypoxic cells in angiogenesis process (Zhong et al., 
1999). Binding the HIFs with the DNA induces expression of several angiogenic factors 
including VEGF, nitric oxide synthase, platelet-derived growth factor (PDGF), and 
others (Ahmed and Bicknell, 2009, Carmeliet, 2005). The critical step in induction of 
this pathway is the stabilization of the HIFs. The most important two members of HIFs 
are HIF-1 and HIF-2. HIF-1 is ubiquitously expressed, while HIF-2 is expressed only in 
endothelial cells and in the kidney, heart, lungs and small intestine (Wang et al., 1995, 
Semenza, 2001). HIF-1 complex is a heterodimer consisting of two DNA binding 
proteins, HIF-1α and HIF-1β. The expression of HIF-1α is tightly regulated by oxygen, 
while the HIF-1β is expressed constitutively (Bracken et al., 2003, Wang et al., 1995). 
Under normoxic conditions, HIF-1α is rapidly degraded due to enzymatic prolyl-
hydroxylation. However, under hypoxic conditions the stability and half life of HIF-1α 
increased remarkably. Accordingly, HIF-1α dimerizes with HIF-1β. The heterodimer is 
then translocated to the nucleus and activates the promoter region of target genes (Wang 
et al., 1995). As the expression of the chief factor in the angiogenesis, VEGF, and many 
angiogenic pathways is related directly with the activation of HIF-1, the search for drugs 
targeting HIF is currently receiving a lot of attention (Semenza, 2003). The notion of 
